I’m sure your profession comes in handy every day on the markets! Thanks for the informative response. What I was basically getting at was with the P2b trial, new variables are being introduced, but with that comes additional risk. Especially when new drug combinations, doses and participants are added - hell there could be an allergic reaction that stops the trial dead in its tracks. The holders here have done an amazing job sharing in depth research for which I am very grateful as a newcomer. On the other hand I am also very aware that the P2b is not a done deal and we could be years away, or may never reach commercialisation. Anyone thinking it’s a done deal is kidding themselves/ ramping.
I’m sure your profession comes in handy every day on the...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |